Suppr超能文献

预期寿命有限的男性的前列腺活检。

Prostate biopsies in men with limited life expectancy.

作者信息

Wasson John H, Bubolz Thomas A, Yao Grace Lu, Barry Michael J

机构信息

Center for the Aging, Dartmouth Medical School, Hanover, NH 03755-3862, USA.

出版信息

Eff Clin Pract. 2002 May-Jun;5(3):137-42.

Abstract

CONTEXT

Authorities discourage prostate screening in men who are likely to die from causes other than prostate cancer.

PRACTICE PATTERN EXAMINED

Use of prostate biopsy-a proxy for screening-in men aged 65 and older with limited life expectancy (i.e., estimated to be less than 10 years).

DATA SOURCE

Five percent samples of Part A (hospital) and Part B (physician) Medicare claims for 1993 through 1997.

RESULTS

22% of all Medicare beneficiaries who underwent a prostate biopsy had a limited life expectancy, corresponding to a rate of 1420 biopsies per 100,000. This rate did not change significantly between 1993 and 1997. For men with a life expectancy greater than 10 years, the biopsy rate was 2,360 per 100,000. Among men with limited life expectancy, in the year following the biopsy, 1.6% had radical prostatectomy and 2.3% had external-beam radiation. Thirty-nine percent were hospitalized.

CONCLUSION

A substantial proportion of prostate biopsies are being performed in men with a life expectancy of less than 10 years. These men are unlikely to benefit from the biopsy or subsequent treatment.

摘要

背景

对于那些很可能死于前列腺癌以外原因的男性,官方不鼓励进行前列腺筛查。

所研究的实践模式

对预期寿命有限(即估计少于10年)的65岁及以上男性使用前列腺活检(作为筛查的替代指标)。

数据来源

1993年至1997年医疗保险A部分(医院)和B部分(医生)索赔的5%样本。

结果

所有接受前列腺活检的医疗保险受益人中,22%预期寿命有限,相当于每10万人中有1420例活检。1993年至1997年期间,该比率没有显著变化。对于预期寿命超过10年的男性,活检率为每10万人2360例。在预期寿命有限的男性中,活检后的一年内,1.6%接受了根治性前列腺切除术,2.3%接受了外照射放疗。39%的人住院治疗。

结论

相当一部分前列腺活检是在预期寿命少于10年的男性中进行的。这些男性不太可能从活检或后续治疗中获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验